The trial will undergo an early feasibility review after 50 randomised patients to ensure full recruitment is likely to be achievable. Patients requiring both conventional thoracic radiotherapy to the primary and stereotactic ablative radiotherapy (SABR) to a thoracic metastasis will be included in a thoracic SABR safety substudy to assess toxicity and planning issues in this unique and challenging subgroup of patients more thoroughly.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile